Business UpdateOct 13, 2026, 08:51 AM
IceCure Medical Highlights Positive Breast Cancer Cryoablation Data at EUSOBI 2026
AI Summary
IceCure Medical Ltd. announced that its ProSense® breast cancer cryoablation technology was featured at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026. The event included scientific presentations, research posters, and clinical workshops. Key clinical data presented showed a 97.5% objective response rate among 40 patients treated with cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, based on 12-month follow-up. The company highlighted strong physician engagement and growing momentum for cryoablation in Europe.
Key Highlights
- IceCure Medical's ProSense® breast cancer cryoablation featured at EUSOBI 2026.
- 12-month clinical data showed 97.5% objective response rate with cryoablation + endocrine therapy (40 patients).
- 91.7% objective response rate with cryoablation alone (24 patients).
- Two scientific presentations highlighted clinical potential and outcomes.
- Two clinical workshops attracted nearly 70 participants each.
- Two scientific posters by ProSense® users were presented.
Price Impact
More from ICCM